![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
(51) | INT.CL. | C07K 16/32 | (2013.01) |
C07K 16/32 | (2006.01) | ||
A61K 31/4745 | (2006.01) | ||
A61K2039/505 | (2013.01) | ||
A61K 31/522 | (2006.01) | ||
C07K2317/24 | (2013.01) | ||
A61P 35/00 | (2006.01) | ||
C07K2317/732 | (2013.01) | ||
A61P 35/02 | (2006.01) | ||
A61K 47/6889 | (2017.08) | ||
A61K 47/6849 | (2017.08) | ||
A61K 47/6851 | (2017.08) | ||
A61K 47/6855 | (2017.08) | ||
A61K 47/6857 | (2017.08) | ||
A61K 47/6863 | (2017.08) | ||
A61K 47/6871 | (2017.08) | ||
A61K 47/6803 | (2017.08) | ||
A61P 1/04 | (2018.01) | ||
A61P 1/18 | (2018.01) | ||
A61P 11/00 | (2018.01) | ||
A61P 13/08 | (2018.01) | ||
A61P 13/10 | (2018.01) | ||
A61P 13/12 | (2018.01) | ||
A61P 15/00 | (2018.01) | ||
A61P 17/00 | (2018.01) | ||
A61P 19/08 | (2018.01) | ||
A61P 25/00 | (2018.01) | ||
A61P 35/00 | (2018.01) | ||
A61P 35/02 | (2018.01) | ||
A61P 37/02 | (2018.01) | ||
A61P 43/00 | (2018.01) |
(11) | Patento numeris | 3092256 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 15734849.1 |
Europos patento paraiškos padavimo data | 2015-01-08 | |
(97) | Europos patento paraiškos paskelbimo data | 2016-11-16 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2022-05-18 |
(46) | Apibrėžties vertimo paskelbimo data |
(86) | Numeris | PCT/CN2015/070379 |
Data | 2015-01-08 |
(87) | Numeris | WO 2015/103989 |
Data | 2015-07-16 |
(30) | Numeris | Data | Šalis |
201410011324 | 2014-01-10 | CN | |
201410011262 | 2014-01-10 | CN | |
201410011362 | 2014-01-10 | CN |
(72) |
LI, Lixin , CN
|
(73) |
Birdie Biopharmaceuticals Inc. ,
Sertus Chambers
P.O. Box 2547
Cassia Court
Camana Bay, Grand Cayman,
KY
|
(54) | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY |
COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY |